Tuhura Biosciences Inc. (HURA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Tuhura Biosciences Inc. (HURA:NASDAQ), powered by AI.

Current Price
$1.41
P/E Ratio
-1.2
Market Cap
26M
Sector
Healthcare
What is the Tuhura Biosciences Inc. stock price forecast?

Tuhura Biosciences Inc. is currently trading at $1.41. View real-time AI analysis on Alpha Lenz.

What is Tuhura Biosciences Inc. insider trading activity?

View the latest insider trading data for Tuhura Biosciences Inc. on Alpha Lenz.

What is Tuhura Biosciences Inc.'s P/E ratio?

Tuhura Biosciences Inc.'s P/E ratio is -1.2.

Tuhura Biosciences Inc.

$1.41
NASDAQHURA
Ask about Tuhura Biosciences Inc.'s future dividend policy...
Alpha Chat Insight

Tuhura Biosciences Inc. trades at a P/E of -1.2 (undervalued) with modest ROE of -332.7%.

Ask for details

Company Overview

Tuhura Biosciences Inc. is a biotechnology company focused on pioneering advancements in the field of genomic and proteomic research. The primary function of Tuhura Biosciences is to develop and provide cutting-edge solutions for the identification and analysis of complex biological data, which is crucial for understanding disease mechanisms and therapeutic targets. Leveraging state-of-the-art technologies, Tuhura aims to enhance drug discovery and development, impacting sectors such as healthcare, pharmaceuticals, and personalized medicine. Tuhura Biosciences Inc. specializes in the integration of advanced analytics and artificial intelligence to improve the accuracy and efficiency of genomic interpretations. This positions the company at the forefront of precision medicine, enabling more targeted and effective treatments. Given the increasing reliance on biotechnology for innovation in medical therapies, Tuhura's contributions are significant within the market, particularly as the global demand for more personalized healthcare solutions continues to grow. With a focus on improving the intersection of biology and technology, Tuhura Biosciences Inc. plays a crucial role in the ongoing transformation of medical research and patient care.

CEODr. James A. Bianco M.D.
SectorHealthcare
IndustryBiotechnology
Employees19

Company Statistics

(FY 2024)

Profile

Market Cap$26.31M
Revenue$0.00
Shares Out0.00
Employees19

Margins

GrossN/A
EBITDAN/A
OperatingN/A
Pre-TaxN/A
NetN/A

Valuation

P/E-1.21
P/B1.80
EV/SalesN/A
EV/EBITDA-0.81
P/FCF-1.78

Growth (CAGR)

Rev 3YrN/A
Rev 5YrN/A
Op Inc 3YrN/A
Op Inc 5YrN/A
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROA-178.25%
ROE-332.67%
ROIC-144.23%

Financial Health

Cash & Cash Equivalents$12.66M
Net Debt$-7.28M
Debt/Equity36.81%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Tuhura Biosciences Inc. (Healthcare) Stock Forecast & Analysis $1.41 | Alpha Lenz